Applied BioCode Corporation

Equities

6598

KYG0488D1051

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
20.55 ^TWD	-1.44%		+2.75%	-18.77%

Apr. 15	Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only	CI
Mar. 21	Applied BioCode Announces CEO Changes	CI

Applied BioCode Appoints Chris Bernard as Chief Executive Officer

March 24, 2022 at 01:30 pm EDT

Applied BioCode announced that Chris Bernard has been appointed as their new Chief Executive Officer (CEO). Mr. Bernard joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology. Most recently Chris was CEO of Oncogenesis Inc.

Latest news about Applied BioCode Corporation

Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only	Apr. 15	CI
Applied BioCode Announces CEO Changes	Mar. 21	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Applied BioCode Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Applied BioCode Appoints Beth Laderman as Chief Scientific Officer	23-09-28	CI
Applied BioCode Corporation Announces the Resignation of Michael Sean Aye as Research and Development Officer	23-09-22	CI
Applied BioCode Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
Applied BioCode Corporation Announces the Change of Representative of Institutional Director	23-06-14	CI
Applied Biocode Corporation Announces the Launch of the Fungal Panel Assay for Research Use	23-06-12	CI
Applied BioCode Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Applied BioCode Corporation Announces Distribution Agreement with Medline Industries	23-05-08	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Applied BioCode Corporation Appoints Liang-Kai Huang as Corporate Governance Officer	23-03-13	CI
Applied Biocode Corporation Announces Revenue Results for the Fourth Quarter and Full Year of 2022	23-02-27	CI
Applied BioCode Corporation Announces Resignation of Craig Griz Adams as Sales Director	23-01-04	CI
Applied BioCode Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Applied BioCode Corporation(TWSE:6598) dropped from S&P Global BMI Index	22-09-19	CI
Applied BioCode Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
Applied Biocode Corporation Announces the Change of Sales Director	22-08-25	CI
Applied BioCode Corporation Announces the Change of Vice President of Operation	22-08-25	CI
Applied BioCode Corporation Announces Change of Sales Director	22-05-17	CI
Applied BioCode Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-27	CI
Applied BioCode Appoints Chris Bernard as Chief Executive Officer	22-03-24	CI

Chart Applied BioCode Corporation

Duration

Period

More charts

Company Profile

Applied BioCode Corp is a is a Taiwan-based company mainly engaged in the provision of automated multiple detection platforms, various application development of detection platforms, as well as the research, development and sale of infectious disease diagnostic reagents. The Company's main products include digital barcode magnetic beads (BMB), optical analyzers, in vitro diagnostic reagents and others. The Company sells in the United States, Europe and Asia markets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

20.55 TWD

Average target price

22 TWD

Spread / Average Target

+7.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
APPLIED BIOCODE CORPORATION	-18.77%	52.78M
EXACT SCIENCES CORPORATION	-26.90%	9.87B
GUARDANT HEALTH, INC.	-16.78%	2.75B
BGI GENOMICS CO., LTD.	-17.50%	2.13B
VERACYTE, INC.	-24.25%	1.65B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+64.58%	1.47B
CAREDX, INC	+31.92%	811M
SEEGENE, INC.	-5.02%	733M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	510M
CURIOX BIOSYSTEMS CO., LTD	+0.20%	300M

Bio Diagnostics & Testing